AUG 2014 ARTICLE LIST >>
PharmaTutor (August- 2014)
ISSN: 2347 - 7881
(Volume 2, Issue 8)
Received On: 06/06/2014; Accepted On: 08/06/2014; Published On: 01/08/2014
AUTHORS: Sagarika Panda1*, Srikanta Patra2
1 Jawaharlal Nehru Technological University Hyderabad, Kukatpally, Hyderabad, Andhra Pradesh, India;
2 National Institute of Pharmaceutical Education & Research (NIPER), Ahmedabad, Gujarat, India
*niperhsagarika@gmail.com
ABSTRACT:
A highly sensitive, selective, reproducible, rapid and stability indicating RP-HPLC and spectrophotometric method has been developed and validated successfully for quantitative evaluation of ivabradine hydrochloride formulations. Chromatography was carried out at 25ºC on a 250 mm x 4.6 mm, 5µm, C18, 100Aº Kromasil column with phosphate buffer pH 7.4: methanol:: 35:65 and U.V. detector at λmax 286 nm. In HPLC method the retention time was about 7.4 minutes. Complete validation study for both the methods was carried out according to ICH guideline. Both methods were found to be selective, linear, accurate and precise in the specified ranges. Linearity of both the methods was achieved in the range 5 to 60 μg/ml with a correlation coefficient (r2) ≥ 0.999. The LOD and LOQ of HPLC method were 0.05 and 0.2 µg/ml, respectively. Intra-day and inter-day variability for both methods were <2% RSD. These methods were successfully used for quantification of ivabradine in drug-release studies from immediate-release tablets and controlled-release (CR) formulations.
How to cite this article: S Panda, S Patra; Rapid and Selective UV Spectrophotometric and RP-HPLC Methods for Dissolution Studies of Ivabradine Controlled-Release Formulations; PharmaTutor; 2014; 2(8); 201-213
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1.Difrancesco D, Camm JA: Heart rate lowering by specific and selective I(f) current inhibition with ivabradine. Drugs. 2004, 64:1757-65.
2. medicines.org.uk/emc/medicine/17188/SPC/Procoralan.
3.Bouchard MF, Simonin G, Bossant MJ, Neyret CB: Simultaneous determination of ivabradine and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromat. B, Analyt. Technol. Biomed. Life Sci. 2000, 745:261-69.
4.Klippert P, Jeanniot JP, Polve S, Lefevre C, Merdjan H: Determination of ivabradine and its N-demethylated metabolite in human plasma and urine, and in rat and dog plasma by a validated high-performance liquid chromatographic method with fluorescence detection. J. Chromat. B, Analyt. Technol. Biomed. Life Sci. 1998, 719:125-33.
5.Prasad UK, Gray D, Purcell H: Review of the If Selective Channel Inhibitor Ivabradine in the Treatment of Chronic Stable Angina. Adv. Ther. 2009, 26:127-37.
6.Duffull SB, Chabaud S, Nony P, Laveille C, Girard P, Aarons L: A Pharmacokinetic simulation model for ivabradine in healthy volunteer. Eur. J. Pharm. Sci. 2000, 10:285-94.
7.Seerapu S, Srinivasan BP: Development and validation of RP-HPLC method for the estimation of ivabradine hydrochloride in tablets. Indian J. Pharm. Sci. 2010, 72:667-71.
8.Rahman MR, Asaduzzaman M, Islam SMA: Development and validation of RP-HPLC method for analysis of Ivabradine Hydrochloride in tablet dosage forms. Res. J. Pharm. Biol. Chem. Sci. 2012, 3:1032-43.
9.Maheshewari S, Khandhar AP, Jain A: Quantitative Determination and Validation of Ivabradine HCL by Stability Indicating RP-HPLC Method and Spectrophotometric Method in Solid Dosage Form. Eurasian J. Anal. Chem. 2010, 5:53-62.
10.Verma RK, Garg S: Validated high performance liquid chromatographic method for analysis of isosorbide mononitrate in bulk material and extended release formulations. J. Pharm. Biomed. Anal. 2002, 30:583-91.
11.ICH Q1A (R2) Stability Testing of New Drug Substances and Products. International Conference on Harmonisation, IFPMA, Geneva, 2003.
12.ICH Q1B Stability Testing of New Drug Substances and Products. International Conference on Harmonisation, IFPMA, Geneva, 1996.
13.Guidance for Industry, Q2B Validation of Analytical procedures: methodologies, US Department of Health and Human Services US FDA, Center for Drug Evaluation and Research, Rockville, MD, USA, November 1996.
14.Guidance for Industry, Oral extended (controlled) release dosage forms: in vivo bioequivalence and in vitro dissolution testing, US Department of Health and Human Services US FDA, Center for Drug Evaluation and Research, Rockville, MD, USA, 1993.
15.Panchagnula R, Bansal T, Varma MVS, Kaul CL: Reversed-phase liquid chromatography with ultraviolet detection for simultaneous quantitation of indinavir and propranolol from ex-vivo rat intestinal permeability studies. J. Chromat. B, Analyt. Technol. Biomed. Life Sci. 2004, 806:277-82.
.png)
